Obstetrics & Gynecology; ACOG
Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheritance. The most common hereditary cancer syndromes related to women’s cancer include hereditary breast and ovarian cancer syndrome, Lynch syndrome, Li...
Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mu...
Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of cancer death. In the general population, BRCA1/2 mutations occur i...
Gershenson, D. et. al.
Aug 11th, 2019 - Management of Rare Ovarian Cancer Histologies. David M. Gershenson, MD1. x. David M. Gershenson.
May 1st, 2019 - The ESMO–ESGO consensus conference manuscript on ovarian cancer was developed by a multidisciplinary panel of 40 leading experts and presents evidence-based recommendations in several areas in an effort to improve the quality of care for women with ovarian cancer. The recommendations focus on pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurre...
The Lancet Oncology; Moore, K. et. al.
Mar 31st, 2019 - Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5–9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line of therapy.
Mar 25th, 2019 - Opportunistic salpingectomy may offer obstetrician–gynecologists and other health care providers the opportunity to decrease the risk of ovarian cancer in their patients who are already undergoing pelvic surgery for benign disease. By performing salpingectomy when patients undergo an operation during which the fallopian tubes could be removed in addition to the primary surgical procedure (eg, h.
Mar 12th, 2019 - For many years after the commercialization of multigene panel testing for hereditary breast and ovarian cancer syndrome, BRCA1 and BRCA2 remained the most commonly identified pathologic variants. Recent studies have found that variants in genes other than BRCA1 or BRCA2 now account for 56% to 71% of pathogenic variants identified among women recently diagnosed with breast cancer. The majority o...
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society; Shafiei F, et al
Mar 4th, 2019 - Results from earlier publications on the association of coffee and caffeine and risk of ovarian cancer are inconsistent.To evaluate the link between coffee, caffeine, caffeinated coffee, and decaffeinated coffee consumption and risk of ovarian cancer.We searched PubMed/Medline, ISI Web of Science, Scopus, and Google Scholar to identify relevant publications up to April 2018. All case–control st...
Disis, M. et. al.
Jan 23rd, 2019 - Question: Does avelumab have clinical activity in the treatment of recurrent or refractory ovarian cancer? Findings: In this phase 1b cohort study, 125 patients with heavily pretreated ovarian cancer (median, 3 prior lines) received avelumab, 10 mg/kg, every 2 weeks. The objective response rate was 9.6%, complete response occurred in 1 patient (0.8%), the 1-year progression-free survival rate w...
Jan 15th, 2019 - The BRCA Exchange aims to advance our understanding of the genetic basis of breast cancer, ovarian cancer and other diseases by pooling data on BRCA1/2 genetic variants and corresponding clinical data from around the world.
Jan 13th, 2019 - Scientists have developed a new test that scans the shapes of tumor cells to select women with especially aggressive ovarian cancer. A team at The Institute of Cancer Research (ICR), London, created an artificial intelligence (AI) tool that looks for clusters of cells within tumors with misshapen nuclei. Findings from the study were published by Heindl et al in Nature Communications.
Packer, M. et. al.
Jan 8th, 2019 - You probably heard that Johnson & Johnson lost a major court battle last year. The company was sued by a group of 22 women who claimed that they developed ovarian cancer as a result of exposure to talcum powder, sold in the form of J&J's iconic Johnson's Baby Powder. A jury ordered the company to pay a record $4.69 billion.
Girion, L. et. al.
Dec 13th, 2018 - Facing thousands of lawsuits alleging that its talc caused cancer, J&J insists on the safety and purity of its iconic product. But internal documents examined by Reuters show that the company's powder was sometimes tainted with carcinogenic asbestos and that J&J kept that information from regulators and the public.
World Ovarian Cancer Coalition
Oct 25th, 2018 - Each year there are an estimated 239,000 women diagnosed with ovarian cancer. Less than half are likely to survive to five years post-diagnosis, and in some countries the figure is much lower.2 Shockingly, using data from two studies,3,4 it is also estimated (conservatively) that one in six women (40,000) lose their lives within three months of being diagnosed. With incidence on the rise, predi...
World Ovarian Cancer Coalition
Oct 25th, 2018 - The World Ovarian Cancer Coalition Every Woman Study was undertaken to address the evidence gap relating to the experiences of woman with ovarian cancer around the world. Our objective for undertaking the study was simple: to identify what needs to be done to tackle this deadly disease and to ensure that every woman diagnosed with ovarian cancer has the best possible chance of survival and best...
Heindl, A. et. al.
Sep 24th, 2018 - How tumor microenvironmental forces shape plasticity of cancer cell morphology is poorly understood. Here, we conduct automated histology image and spatial statistical analyses in 514 high grade serous ovarian samples to define cancer morphological diversification within the spatial context of the microenvironment. Tumor spatial zones, where cancer cell nuclei diversify in shape, are mapped in ...
Apr 24th, 2018 - Non-epithelial ovarian tumours account for approximately 10% of all ovarian cancers.
Apr 10th, 2018 - Learn about the risk factors for ovarian cancer such as age, obesity, reproductive history, fertility drugs, family history of cancer, and other factors.
Committee on Genetics
Mar 5th, 2018 - In 6 March 2018, The U. S.
Feb 12th, 2018 - Importance With approximately 14 000 deaths per year, ovarian cancer is the fifth most common cause of cancer death among US women and the leading cause of death from gynecologic cancer. More than 95% of ovarian cancer deaths occur among women 45 years and older. Objective To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on screening for ovarian cancer. Evide...
US Preventive Services Task Force
Jan 31st, 2018 - The USPSTF recommends against screening for ovarian cancer in asymptomatic women. This recommendation applies to asymptomatic women who are not known to have a high-risk hereditary cancer syndrome.
Oct 31st, 2017 - There has been much interest in the identification of a successful ovarian cancer screening test, in particular, one that can detect ovarian cancer at an early stage and improve survival. We reviewed the currently available data from randomized and observational trials that examine the role of imaging for ovarian cancer screening in average-risk and high-risk women.
American College of Obstetricians and Gynecologists
Sep 2nd, 2017 - Ovarian cancer is the second most common type of female reproductive cancer, and more women die from ovarian cancer than from cervical cancer and uterine cancer combined. Currently, there is no strategy for early detection of ovarian cancer that reduces ovarian cancer mortality.
American College of Obstetricians and Gynecologists
Aug 31st, 2017 - This Practice Bulletin focuses on the primary genetic mutations associated with hereditary breast and ovarian cancer syndrome, BRCA1 and BRCA2, but also will briefly discuss some of the other genes that have been implicated.
Feb 13th, 2017 - Information for health care providers about the CA-125 test as a screen for ovarian cancer.
Nov 30th, 2016 - Methodological limitations in studying the association between the use of fertility drugs and cancer include the inherent increased risk of cancer in women who never conceive, the low incidence of most of these cancers, and that the age of diagnosis of cancer typically is many years after fertility drug use. Based on available data, there does not appear to be a meaningful increased risk of inv.
Alexi A. Wright
Sep 30th, 2016 - To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Sep 22nd, 2016 - The guidelines will focus on cancer prevention and screening among individuals known to harbour a pathogenic BRCA1/2 mutation. The presence of a BRCA1 or BRCA2 mutation accounts for the majority of hereditary breast and ovarian cancer syndromes.
Morgan, R.,et al
Aug 31st, 2016 - This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and current algorithms were revised for the 2016 update. The new LCOHs algorithms include clear cell carcinomas, mucinous carcinomas, and grade 1 (low-grade) serous carcinomas/endometrioid epithelial carcinomas.
Society of Gynecologic Oncology and American Society of Clinical Oncology
Aug 29th, 2016 - To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Society of Gynecologic Oncology
Oct 14th, 2014 - Women diagnosed with epithelial ovarian, tubal, and peritoneal cancers should receive genetic counseling and be offered genetic testing, even in the absence of a family history.
Society of Gynecologic Oncology
Nov 14th, 2013 - Salpingectomy may be appropriate and feasible as a strategy for ovarian cancer risk reduction.
Society of Gynecologic Oncology
Nov 14th, 2013 - To explore the value of multiple clinical endpoints in the unique setting of ovarian cancer.
Gynecologic Oncology; Timmermans M, van der Aa MA et. al.
Jul 13th, 2018 - Treatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and (neo)adjuvant platinum-based chemotherapy. The aim of this study was to evaluate whether the time from surgery to adjuvant chemotherapy (TTC) was associated with clinical outcome. We identified all Dutch patients who received optimal or complete debulking surgery for primary EOC (FIGO IIb-IV) between 2008 a...
Obstetrics and Gynecology; Melamed A, Nitecki R et. al.
Apr 6th, 2017 - To compare 3-year survival, length of hospitalization, perioperative mortality, risk of readmission, and residual disease associated with laparoscopic and laparotomic interval debulking surgery among women with epithelial ovarian cancer. We used the National Cancer Database to identify a cohort of patients diagnosed with stage IIIC and IV epithelial ovarian cancer between 2010 and 2012 who unde...
BMJ (Clinical Research Ed.); Holme Ø, Schoen RE et. al.
Jan 14th, 2017 - To compare the effectiveness of flexible sigmoidoscopy in screening for colorectal cancer by patient sex and age. Pooled analysis of randomised trials (the US Prostate, Lung, Colorectal and Ovarian cancer screening trial (PLCO), the Italian Screening for Colon and Rectum trial (SCORE), and the Norwegian Colorectal Cancer Prevention trial (NORCCAP)). Aggregated data were pooled from each randomi...
Obstetrics and Gynecology; Power L, Lefas G et. al.
Apr 7th, 2016 - To evaluate whether hormone therapy (HT) after nonserous epithelial ovarian cancer is associated with a decrease in overall and disease-free survival. We conducted a retrospective cohort study. The Manitoba Cancer Registry and Drug Programs Information Network were searched to find all women with known nonserous epithelial ovarian, fallopian tube, or primary peritoneal cancer between 1995 and 2...
Obstetrics and Gynecology; van Nagell JR, Miller RW
Apr 7th, 2016 - Data from screening trials indicate that a significant percent of asymptomatic women older than 50 years of age will develop ovarian abnormalities that are detectable by ultrasonography. Most of these abnormalities are benign, and many will resolve spontaneously. However, the risk of ovarian cancer, particularly in postmenopausal women, is of concern. The goal is to use a diagnostic and treatme...
Gastroenterology Schoen RE, Razzak A et. al.
Aug 9th, 2015 - Little is known about the change in risk conferred by family history of colorectal cancer (CRC) as a person ages. We evaluated the effect of family history on CRC incidence and mortality after 55 years of age, when the risk of early onset cancer had passed. We collected data from participants in the randomized, controlled Prostate, Lung, Colorectal and Ovarian cancer screening trial of flexible...
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Wright AA, Cronin A et. al.
Aug 4th, 2015 - A 2006 randomized trial demonstrated a 16-month survival benefit with intraperitoneal and intravenous (IP/IV) chemotherapy administered to patients who had ovarian cancer, compared with IV chemotherapy alone, but more treatment-related toxicities. The objective of this study was to examine the use and effectiveness of IP/IV chemotherapy in clinical practice. Prospective cohort study of 823 wome...
Lancet (London, England); , Beral V et. al.
Feb 16th, 2015 - Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Individual participant datasets from 52 epidemiological studies were analysed centrall...
Journal of the National Cancer Institute; Falconer H, Yin L et. al.
Jan 29th, 2015 - Recent genetic and morphologic studies have challenged the traditional view on the pathogenesis of ovarian cancer; suggesting that ovarian cancer predominantly arises within the fallopian tubes or the uterus. We hypothesize that surgical removal of the fallopian tubes is associated with a reduced risk for ovarian cancer. In this population-based cohort study, we used data on women with previous...
Obstetrics and Gynecology;
Jan 6th, 2015 - Ovarian cancer has the highest mortality rate out of all types of gynecologic cancer and is the fifth leading cause of cancer deaths among women. Current attempts at screening for ovarian cancer have been unsuccessful and are associated with false-positive test results that lead to unnecessary surgery and surgical complications. Prophylactic salpingectomy may offer clinicians the opportunity to...
JAMA O'Brien KM, Tworoger SS et. al.
Jan 7th, 2020 - The relationship between use of powder in the genital area and ovarian cancer is not established. Positive associations reported in case-control studies have not been confirmed in cohort studies. To estimate the association between use of powder in the genital area and ovarian cancer using prospective observational data. Data were pooled from 4 large, US-based cohorts: Nurses' Health Study (enr...
JAMA Network Open; Loomans-Kropp HA, Pinsky P et. al.
Dec 4th, 2019 - Aspirin use has been associated with reduced risk of cancer mortality, particularly of the colorectum. However, aspirin efficacy may be influenced by biological characteristics, such as obesity and age. With the increasing prevalence of obesity and conflicting data regarding the effect of aspirin in older adults, understanding the potential association of aspirin use with cancer mortality accor...
JAMA , Owens DK et. al.
Aug 20th, 2019 - Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is the most common cancer after nonmelanoma skin cancer and the second leading cause of cancer death. In the general population, BRCA1/2 mutations occur in an estimat...
Menopause (New York, N.Y.); Harder H, Starkings RML et. al.
Jul 10th, 2019 - Sexual well-being can contribute significantly to the overall quality of women's lives. This qualitative study aimed to examine sexual activity, functioning, and satisfaction in a large sample of postmenopausal women from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) METHODS:: Thematic analysis was used to evaluate the free-text data of the Fallowfield Sexual Activity Questio...
FoundationOne CDx is the first FDA-approved broad companion diagnostic (CDx) that is clinically and analytically validated for solid tumors
For US Healthcare Professionals. View Indications, Usage & Full Prescribing Information
Learn how STEALTH® liposomes enable DOXIL® to penetrate the leaky membranes often found in cancer tissue while evading detection by the immune system. Access information about DOXIL® across indications.
Gemzar. GEMZAR (gemcitabine for injection), for intravenous use. Initial U.S. Approval: 1996 ..... http://www.osha.gov/SLTC/hazardousdrugs/index.html. 2.7.
THIS SITE IS INTENDED FOR HEALTHCARE PROFESSIONALS ONLY.
LYNPARZA® (olaparib) is an FDA-approved PARP inhibitor for maintenance therapy of recurrent ovarian cancer or gBRCAm HER2-negative metastatic breast cancer.
Learn about Avastin® (bevacizumab) for FDA approved indications. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (rOC) Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial
Learn about Rubraca® (rucaparib) tablets, a maintenance therapy for patients with recurrent ovarian cancer
Proceedings of the National Academy of Sciences of the United States of America; Zhao Y, Cao J et. al.
Jan 19th, 2019 - In ovarian cancer patients, tumor fibrosis and angiotensin-driven fibrogenic signaling have been shown to inversely correlate with survival. We sought to enhance drug delivery and therapeutic efficacy by remodeling the dense extracellular matrix in two orthotopic human ovarian carcinoma xenograft models. We hypothesized that targeting the angiotensin signaling axis with losartan, an approved an...
Journal of the National Cancer Institute; Terry MB, Daly MB et. al.
Nov 29th, 2018 - There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast cancer risk using a prospective cohort of 17 917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations). During a median follow-up of 10.7 years, 1046 wome...
Obstetrics and Gynecology; van Nagell JR, Burgess BT et. al.
Oct 11th, 2018 - To estimate the effect of ultrasound screening on stage at detection and long-term disease-specific survival of at-risk women with epithelial ovarian cancer. Eligibility included all asymptomatic women 50 years of age or older and women 25 years of age or older with a documented family history of ovarian cancer. From 1987 to 2017, 46,101 women received annual ultrasound screening in a prospecti...
Obstetrics and Gynecology; Robertson SE, Peipert JF
Oct 11th, 2018 - Ultrasound Screening for Ovarian Cancer: Are We There Yet?|2018|Robertson SE,Peipert JF,|
JAMA Gross AL, Blot WJ et. al.
Aug 18th, 2018 - BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.|2018|Gross AL,Blot WJ,Visvanathan K,|genetics,statistics & numerical data,genetics,
Gynecologic Oncology; Zhang XS, Zhang YM et. al.
Jul 1st, 2018 - Recent epidemiological studies have investigated the associations between the use of bisphosphonates and the development of endometrial cancer and ovarian cancer; these studies have shown controversial results. Hence, this meta-analysis was conducted to evaluate the changes in the risks of developing endometrial and ovarian cancers after using bisphosphonates based on current evidence. A compre...
Gynecologic Oncology; Ruscito I, Darb-Esfahani S et. al.
May 13th, 2018 - To investigate the association of cancer stem cell biomarker aldehyde dehydrogenase-1 (ALDH1) with ovarian cancer patients' prognosis and clinico-pathological characteristics. The electronic searches were performed in January 2018 through the databases PubMed, MEDLINE and Scopus by searching the terms: "ovarian cancer" AND "immunohistochemistry" AND ["aldehyde dehydrogenase-1" OR "ALDH1" OR "ca...
JAMA Oncology; Kotsopoulos J, Gronwald J et. al.
May 1st, 2018 - Prophylactic bilateral salpingo-oophorectomy is recommended for BRCA1 mutation carriers to prevent ovarian cancer. Whether or not hormone replacement therapy (HRT) initiated after oophorectomy is associated with an increased risk of breast cancer has not been evaluated in a prospective study. To determine the association between HRT use and BRCA1-associated breast cancer. A prospective, longitu...
JAMA , Grossman DC et. al.
Feb 16th, 2018 - With approximately 14 000 deaths per year, ovarian cancer is the fifth most common cause of cancer death among US women and the leading cause of death from gynecologic cancer. More than 95% of ovarian cancer deaths occur among women 45 years and older. To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on screening for ovarian cancer. The USPSTF reviewed the evidence o...
JAMA Henderson JT, Webber EM et. al.
Feb 16th, 2018 - Ovarian cancer is relatively rare but the fifth-leading cause of cancer mortality among United States women. To systematically review evidence on benefits and harms of ovarian cancer screening among average-risk women to inform the United States Preventive Services Task Force. MEDLINE, PubMed, Cochrane Collaboration Registry of Controlled Trials; studies published in English from January 1, 200...
PloS One; Luo H, Xu X et. al.
Jan 30th, 2018 - The prognostic role of human epidermal growth factor receptor 2 (HER2) in ovarian cancer has been investigated in previous studies, but the results remain controversial. Here we present a meta-analysis to systematically review the association between HER2 expression and ovarian cancer prognosis. Observational studies published until July 2017 were searched in Pubmed, Embase, and Cochrane librar...
International Journal of Cancer; Reger MK, Zollinger TW et. al.
Nov 8th, 2017 - Experimental studies have revealed that phytoestrogens may modulate the risk of certain sites of cancer due to their structural similarity to 17β-estradiol. The present study investigates whether intake of these compounds may influence prostate cancer risk in human populations. During a median follow up of 11.5 years, 2,598 cases of prostate cancer (including 287 advanced cases) have been ident...
Obstetrics and Gynecology;
Aug 23rd, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and management of ovarian cancer and for simplicity in this document, ovarian cancer also refers to fallopian tube cancer and primary peritoneal cancer. Clinical g...
Gynecologic Oncology; Oliver KE, Brady WE et. al.
Aug 15th, 2017 - We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (cle...
Cancer Chemotherapy and Pharmacology; Mendivil AA, Rettenmaier MA et. al.
Jul 2nd, 2017 - Hyperthermic intraperitoneal chemotherapy (HIPEC) potentially confers significant survival benefits in the management of ovarian cancer although the long-term data remain scant. We sought to compare the survival rates of advanced stage ovarian cancer patients who were treated with primary induction therapy alone or in conjunction with consolidation HIPEC. 69 ovarian cancer patients who underwen...
British Journal of Cancer; Russell MR, Graham C et. al.
Jun 30th, 2017 - There is an urgent need for biomarkers for the early detection of ovarian cancer (OC). The purpose of this study was to assess whether changes in serum levels of lecithin-cholesterol acyltransferase (LCAT), sex hormone-binding globulin (SHBG), glucose-regulated protein, 78 kDa (GRP78), calprotectin and insulin-like growth factor-binding protein 2 (IGFBP2) are observed before clinical presentati...
Gynecologic Oncology; Moss HA, Havrilesky LJ et. al.
Jun 23rd, 2017 - The Patient Protection and Affordable Care Act (ACA) included provisions to expand insurance coverage by expanding Medicaid eligibility, providing subsidies of private coverage and enforcing an individual mandate. The objective of this study is to examine the impact of the ACA on insurance rates among women diagnosed with a gynecologic malignancy. Using Surveillance, Epidemiology, and End Resul...
Annals of Surgical Oncology; Minig L, Heitz F et. al.
Jun 13th, 2017 - The aim of this study was to determine oncological outcomes and incidence of lymph node (LN) metastases in women who underwent systematic pelvic and paraaortic lymphadenectomy for surgical staging of apparent stage I low-grade epithelial ovarian cancer (LGEOC). A retrospective study was performed at nine institutions across Europe and the US, and patients who underwent surgical staging for pres...
Targeted Oncology; Kuk A, Magnowska M et. al.
Jun 5th, 2017 - Bevacizumab is used in addition to standard, platinum-based chemotherapy to treat advanced-stage ovarian cancer patients. Thrombosis is a well-documented adverse effect of bevacizumab. The aim of this study was to identify predictive parameters for thromboembolic events in ovarian cancer patients and to explain how bevacizumab increases the risk of these events. Fifty-seven FIGO stage III ovari...
Climacteric : the Journal of the International Menopause Society; Ma XM, Sun X et. al.
Jun 1st, 2017 - The platelet-to-lymphocyte ratio (PLR) is a predictive clinical biomarker for different cancers. However, the results of several studies investigating the association between the PLR and the prognosis of ovarian cancer have been inconclusive. Therefore, there is a need to conduct a meta-analysis to estimate the prognostic value of the PLR in ovarian cancer. We searched the EMBASE, Medline, PubM...
Diabetes Research and Clinical Practice; Zhang D, Li N et. al.
May 29th, 2017 - Diabetes mellitus (DM) is hypothesized to be associated with an increased risk of ovarian cancer (OC), but current evidences are inconsistent. We aimed to further study this association. PubMed, EMBASE, Web of Science, and Scopus were searched for eligible articles. After descriptive summary of the data, a random-effects model was applied in quantitative synthesis. Subgroup analysis was perform...
American Journal of Epidemiology; Qin B, Moorman PG et. al.
May 23rd, 2017 - This study evaluated 3 index-based dietary patterns-Healthy Eating Index (HEI)-2005, HEI-2010, and Alternate Healthy Eating Index (AHEI)-2010-in relation to ovarian cancer risk in African-American women. The study was conducted among 415 ovarian cancer cases and 629 age- and site-matched controls of African-American descent recruited from the population-based African American Cancer Epidemiolog...
Gynecologic Oncology; Colon-Otero G, Weroha SJ et. al.
May 3rd, 2017 - We report the results of a phase 2 clinical trial of the combination of everolimus and letrozole in patients with relapsed estrogen receptor-positive high-grade ovarian cancer. The trial's primary endpoint was the proportion of patients alive and progression-free after 12weeks of therapy with the combination of everolimus and letrozole. A 12-week PFS of 45% or greater was considered a positive ...
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society; May T, Comeau R et. al.
Apr 25th, 2017 - The management of women with advanced-stage serous ovarian cancer includes a combination of surgery and chemotherapy. The choice of treatment with primary debulking surgery or neoadjuvant chemotherapy varies by institution. The objective of this study was to report 5-year survival outcomes for ovarian cancer patients treated at a single institution with primary debulking surgery or neoadjuvant ...
Gynecologic Oncology; Katchman BA, Chowell D et. al.
Apr 21st, 2017 - Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer. To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n=30 cases/30 healthy controls) and measured bound Ig...
Cancer Research; Ose J, Poole EM et. al.
Apr 6th, 2017 - Invasive epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The etiology of EOC remains elusive; however, experimental and epidemiologic data suggest a role for hormone-related exposures in ovarian carcinogenesis and risk factor differences by histologic phenotypes and developmental pathways. Research on prediagnosis androgen concentrations and EOC risk has yielded incon...
Gynecologic Oncology; McGee J, Giannakeas V et. al.
Mar 20th, 2017 - Preventive breast surgery and MRI screening are offered to unaffected BRCA mutation carriers. The clinical benefit of these two modalities has not been evaluated among mutation carriers with a history of ovarian cancer. Thus, we sought to determine whether or not BRCA mutation carriers with ovarian cancer would benefit from preventive mastectomy or from MRI screening. First, the annual mortalit...
Cancer Causes & Control : CCC; Poole EM, Lin WT et. al.
Mar 16th, 2017 - Endometriosis is associated with ovarian cancer, but the relation with endometrial cancer is unclear. Prior studies generally were retrospective and had potential limitations, including use of self-reported endometriosis, failure to account for delays between symptom onset and endometriosis diagnosis, and changes in risk factors post-endometriosis diagnosis. We evaluated whether these limitatio...
Cancer Causes & Control : CCC; Shafrir AL, Schock H et. al.
Mar 15th, 2017 - Oral contraceptives (OCs) have been consistently associated with a reduced ovarian cancer risk; however, most previous studies included women in older birth cohorts using high-dose OC formulations. We assessed OC use, including type and dose, and ovarian cancer risk among women born between 1947 and 1964 using more recent formulations. We included 110,929 Nurses' Health Study II participants. W...
Journal of Minimally Invasive Gynecology; Bogani G, Borghi C et. al.
Feb 22nd, 2017 - Few studies investigated the efficacy and safety of minimally invasive surgery for the treatment of early-stage epithelial ovarian cancer (eEOC). In this context, we aimed to review the current evidence comparing laparoscopy and the laparotomic approach for staging procedures in eEOC. This systematic review was registered in the International Prospective Register of Systematic Reviews. Overall,...
Gynecologic Oncology; Kentwell M, Dow E et. al.
Feb 6th, 2017 - Owing to the rapid increase in clinical need, we aimed to implement and review the performance of a mainstreaming model of germline BRCA1/2 genetic testing in eligible women with high grade non-mucinous epithelial ovarian cancer via a Genetic Counselor embedded in the gynecology oncology clinic. The model implemented involved a specialized referral form, weekly genetics-lead multidisciplinary r...
Cancer Causes & Control : CCC; Koushik A, Grundy A et. al.
Jan 19th, 2017 - Hormone-related factors have been associated with ovarian cancer, the strongest being parity and oral contraceptive use. Given reductions in birth rates and increases in oral contraceptive use over time, associations in more recent birth cohorts may differ. Furthermore, consideration of ovarian cancer heterogeneity (i.e., Type I/II invasive cancers) may contribute to a better understanding of e...
Gynecologic Oncology; Kessous R, Laskov I et. al.
Jan 3rd, 2017 - To evaluate clinical outcome in patients selected to receive neoadjuvant chemotherapy (NACT) compared to primary debulking surgery (PDS). Retrospective study including all consecutive patients diagnosed and treated for advanced (stages III-IV) ovarian cancers between the years 2003-2015. 263 women were included in the study, of these, 127 patients were selected to receive NACT and 136 were trea...
JAMA Oncology; Neidhardt G, Hauke J et. al.
Dec 29th, 2016 - Germline mutations in established moderately or highly penetrant risk genes for breast cancer (BC) and/or ovarian cancer (OC), including BRCA1 and BRCA2, explain fewer than half of all familial BC and/or OC cases. Based on the genotyping of 2 loss-of-function (LoF) variants c.5101C>T (p.GIn1701Ter [rs147021911]) and c.5791C>T (p.Arg1931Ter [rs144567652]), the FANCM gene has been suggested as a ...
Cancer Causes & Control : CCC; Bethea TN, Palmer JR et. al.
Dec 27th, 2016 - Extensive data in White women have linked oral contraceptive use, tubal ligation, and parity to reduced risk of ovarian cancer; results on postmenopausal female hormone use are mixed. Few studies, all of which are case-control studies, have been undertaken among Black women. The aim of the present study was to prospectively assess associations of reproductive factors and exogenous hormones with...
American Journal of Obstetrics and Gynecology; Hanley GE, McAlpine JN et. al.
Nov 4th, 2016 - Ovarian cancer is the leading cause of death due to gynecologic malignancy and the fifth most common cause of cancer deaths in developed countries. Recent evidence has indicated that the most common and lethal form of ovarian cancer originates in the distal fallopian tube, and recommendations for surgical removal of the fallopian tube (bilateral salpingectomy) at the time of other gynecologic s...
Obstetrics and Gynecology; Lee AW, Ness RB et. al.
Apr 7th, 2016 - To describe the association between postmenopausal estrogen-only therapy use and risk of ovarian carcinoma, specifically with regard to disease histotype and duration and timing of use. We conducted a pooled analysis of 906 women with ovarian carcinoma and 1,220 women in a control group; all 2,126 women included reported having had a hysterectomy. Ten population-based case-control studies parti...
Lancet (London, England); Jacobs IJ, Menon U et. al.
Dec 28th, 2015 - Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 years. We designed this trial to establish the effect of early detection by screening on ovarian cancer mortality. In this randomised controlled trial, we recruited postmenopausal women aged 50-74 years from 13 centres in National Health Service Trusts in England, Wales, and Northern Ireland. Exclusion criteria were prev...
Obstetrics and Gynecology; Cress RD, Chen YS et. al.
Aug 5th, 2015 - To identify characteristics associated with long-term survival for patients with epithelial ovarian cancer using the California Cancer Registry. A descriptive analysis of survival of all California residents diagnosed with epithelial ovarian cancer between 1994 and 2001 was conducted using patients identified through the cancer registry with follow-up through 2011. Characteristics of the patien...
JAMA Oncology; Metcalfe K, Lynch HT et. al.
Jul 16th, 2015 - Women who carry a germline mutation in either the BRCA1 or BRCA2 gene face a lifetime risk of breast cancer of up to 70%, and once they receive a diagnosis of breast cancer, they face high risks of both second primary breast and ovarian cancers. Preventive bilateral salpingo-oophorectomy is recommended to women with a BRCA mutation at age 35 years or thereafter to prevent breast and ovarian can...
JAMA Rebbeck TR, Mitra N et. al.
Apr 7th, 2015 - Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists. To identify mutation-specific cancer risks for carriers of BRCA1/2. Observational study of women who were ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 or BRCA2 mutations. The international sample comprised 19,581 carriers of BR...
Lancet (London, England); Dizon DS
Sep 16th, 2017 - PARP inhibitors for targeted treatment in ovarian cancer.|2017|Dizon DS,|methods,drug therapy,genetics,mortality,pathology,therapeutic use,therapeutic use,therapeutic use,genetics,
American Journal of Obstetrics and Gynecology; Antosh DD, High R et. al.
Jul 24th, 2017 - The American Congress of Obstetricians and Gynecologists recommends that "the surgeon and patient discuss the potential benefits of the removal of the fallopian tubes during a hysterectomy in women at population risk of ovarian cancer who are not having an oophorectomy," resulting in an increasing rate of salpingectomy at the time of hysterectomy. Rates of salpingectomy are highest for laparosc...
American Journal of Obstetrics and Gynecology; Cadish LA, Shepherd JP et. al.
Jun 17th, 2017 - Fallopian tubes are commonly removed during laparoscopic and open hysterectomy to prevent ovarian and tubal cancer but are not routinely removed during vaginal hysterectomy because of perceptions of increased morbidity, difficulty, or inadequate surgical training. We sought to quantify complications and costs associated with a strategy of planned salpingectomy during vaginal hysterectomy. We cr...